You are visitor 51
Wednesday March 10, 2010






Mission & Values

International Pharmaceutical Academy (IPA) is a progressive Canadian organization dedicated to be the primary provider of Quality Education and Training for the Pharmaceutical, Medical Devices, Biologics, Cosmetics, and Allied Industries.

We present experts from industry, academia and government agencies. Providing the best in educational instruction in short course formats together with carefully orchestrated workshops.

IPA Future Events - (Please click here for a full listing of our events)

6th Annual Stability Testing Conference
Pharmaceutical and Biopharmaceutical Stability:
Current Trends and Best Practices to Support Global Markets

March 23-24, 2010 | Somerset, NJ - USA

Conference Topics

  • Regulatory Requirements for Stability Testing - FDA, Health Canada, WHO and ICH Guidelines; Q1A, Q1C, Q1D, Q1E, Q1F, Q2A, Q2B, Q3A and Q3B
  • Stability Studies and the Product Life Cycle
  • Update on the WHO Stability Guideline
  • How to Calculate Product Expiry after Excursions
  • Designing and Implementing an Effective Commercial (Marketed products) Stability Program
  • Requirements for Stability Testing - API and Formulation Impurities
  • Stress Testing of APIs and Drug Products
  • Stability Indicating Profile for Biotechnology Products: Considerations for Development of Stability Testing Program for Biopharmaceuticals
  • Vaccine Shelf Life and Post-licensure Stability Studies
  • Implementation of the WHO Guideline on Stability Evaluation of Vaccines
  • The Methodology for calculating Stability and Release Limits
  • Setting Specifications for Drug Products
  • Strategies for Ensuring Regulatory and cGMP Compliance of Outsourced Stability Programs
  • Quality by Design (QbD) and Stability Testing
  • Q1E – ICH Harmonised Tripartite Guideline – Evaluation for Stability Data
  • Using Practical Statistics to Interpret Stability Results
  • Stability Challenges of Biologics
  • Forced Degradation Studies Predict Effects on Bio-products in Drug Development and Manufacture
  • Use of Statistics to Establish a Stability Trend – Matrixing & Bracketing
  • Stability Testing in Challenging Storage Environments
  • Stability Challenges of OTCs, Nutraceuticals and Combination Products
  • Post Marketing Stability Evaluation
  • Evaluating Product Quality After a Temperature Excursion
GMP Chapter
Effective Quality Assurance Auditing

April 14-15, 2010 - Montreal, Canada

Identify opportunities to improve your internal audit activity's ability to add value and improve operations - and develop actions to move forward on the path to quality

This two-day "hands on" training course & workshops will address various topics, techniques, tools and methods for auditing including:

  • Audit Standards
  • Auditing to U.S. drug (21CFR Part 210/211) and device (21CFR Part 820) good manufacturing practices and the QSR 
  • Auditing to European Union directives
  • Auditing to ISO Standards
  • Role Characteristics of the Auditor
  • Auditing Techniques 
  • The Audit Process 
  • Audit Mechanics 
  • Requirements of the Standard Being Audited
  • Internal Facility Audits
  • External Audits
  • Product, process, procedural and system audits
  • Auditing Packaging and labeling system
  • Auditing Laboratory Control System
  • Evaluate Audit Results
  • Preparing Audit Reports results
  • What makes a Good Audit
New addition to Health Canada's GMP regulation
Annual Product Quality Review (APQR) and Annual Product Review(APR)

March 24 - 25, 2010 | Toronto, Canada

A Two day comprehensive course with workshops on:

  • Annual Product Quality Review (APQR) - Interpret Health Canada’s regulatory requirements
  • US FDA CFR 211, § 211.180
  • ICH Annual Review Content
  • Product Quality Review (EU GMP Guide)
  • Annual Product Quality Review, AQPR (Canadian GMP) Vs. Annual Product Review (US, FDA)
  • Developing Standard Operating Procedures (SOPs) - What should be included
  • Best Practices for Writing AQPR Reports
  • Proposed Chapters of a Product Quality Review (PQR)
  • Documentation for APRs - Format and Methods of APR Documentation
  • Implementing Best Practices for Writing Annual Reports
  • Overview for CMC Section of Annual Reports
  • CMC Section Table of Contents
  • Quality-by-Design (QbD) paradigm and Annual Product Quality Review, (APQR) and Annual Reports (AR) 
Computer Systems Validation

April 14-15, 2010 - Montreal, Canada

Featuring In-Depth Presentations, Case-Studies & Workshops on:

  • Regulatory Expectations
  • Perspective from the FDA: 21 CFR Part 11 Compliance and Computer Validation
  • Determine Which Systems Need to be Validated
  • Software Validation Requirements for:
  • Spreadsheets
  • Production Equipment
  • Lab Equipment
  • Data Migration
  • User Requirement Specifications (URS)
  • Design Specifications
  • Compiling the Validation Master Plan (VMP)
  • Qualification Requirements (IQ,OQ, PQ)
  • Preparing Validation Summary Reports
  • Requirements for Off the Shelf (OTS) Software
  • Validation Planning and Project Management
  • Effective Software Testing
  • Auditing GxP Computer Systems
  • Auditing Software Vendors
  • Assessing the Impact of Software Changes

Workshop

  • System Retirement
  • Auditing GxP Computer Systems

Interactive Exercises

  • Performing a Self Audit of GxP Computer Systems for your Site
  • Participants will review of a variety of scenarios, and using the given templates and questionnaires will evaluate the pros and cons
Quality Risk Management

March 30-31, 2010 - Somerset, NJ, USA

A Two-day interactive course with workshops, case studies and Interactive exercises on:

  • Risk Management Basics
  • The ISO 31000 global risk management process model
  • Current Risk Management initiatives (ICH, FDA, ISO etc.) and regulatory expectations
  • Why do Risk Management attempts fail?
  • Benefits of a Risk Management Program
  • Introduction to A System Approach to Total Life Cycle Risk Management
  • Effective Risk Management Process:
    • Hazard Identification
    • Risk Characterization
    • Risk Estimation
    • Risk Evaluation
    • Risk Controls
    • Critical Control Point Analysis
    • Residual Risk
    • Monitoring and Feedback
  • Risk Assessment Tools:
    • Process Mapping
    • Hazard Analysis and Critical Control Points (HACCP)
    • Hazard Operability Analysis (HAZOP)
    • Fault Tree Analysis (FTA)
    • Cause and Effect Analysis
    • Failure Mode Effects Analysis (FMEA) etc.
  • Risk Management Principles
    • Risk Review
    • Risk Acceptability
    • Risk Communication
    • Risk Control
    • Effectiveness of Risk Control
  • Integration of Risk Management with Quality Management
    • Risk Management Plan (RMP)
    • Corrective and Preventative Actions
    • Composing scientific justifications
    • Effectiveness evaluation
    • Risk Management Audit

What's new?




Health Canada Informs Pregnant and Breastfeeding Women Not to Take Vitamin Maxum Matragen and/or Maxum Multi Vite Supplements

Health Canada is advising expectant mothers and breastfeeding women not to take the vitamin-mineral supplements Maxum Matragen or Maxum Multi-Vite by Seroyal International Inc. Maxum Multi-Vite has been approved as a vitamin-mineral supplement for only the general public but lacks the required cautionary statement on the label regarding pregnant and/or breast feeding women. The product Maxum Matragen is being promoted by the company as a prenatal supplement; however, neither product has been authorized for sale by Health Canada for use by women who are pregnant or breastfeeding. Read More

A Small Number of Bottles of the Antibiotic Rofact® (Rifampin) May Contain a Different Drug

Health Canada is warning consumers that there is a small possibility that some bottles of one lot of Rofact® (rifampin), an antibiotic used to treat tuberculosis (TB) and some other infections, may contain the drug clonazepam instead of the antibiotic rifampin. The affected lot number of Rofact® is 8K5467, and the Drug Identification Number (DIN) is 00343617. Clonazepam is an anti-epileptic medication and has sedating properties. The manufacturer, Valeant Canada, is initiating a recall to the retail level. Read More

Update - Health Canada Reviewing Hydroxycut Products in light of U.S. Advisory

Health Canada is updating Canadians about Hydroxycut products. On May 1, 2009, the U.S. Food and Drug Administration (FDA) issued a public warning regarding certain Hydroxycut products. The FDA is advising U.S. consumers to stop using Hydroxycut products as there have been reports of liver injuries potentially associated with this product in the United States. Read More

To Submit Your News

 

Copyright © 2010 www.ipacanada.com - International Pharmaceutical Academy - All Rights Reserved.